It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The presence of actinic keratoses (AKs) increases a patient’s risk of developing squamous cell carcinoma by greater than six-fold. We evaluated the effect of topical treatment with imiquimod on the tumor microenvironment by measuring transcriptomic differences in AKs before and after treatment with imiquimod 3.75%. Biopsies were collected prospectively from 21 patients and examined histologically. RNA was extracted and transcriptomic analyses of 788 genes were performed using the nanoString assay. Imiquimod decreased number of AKs by study endpoint at week 14 (p < 0.0001). Post-imiquimod therapy, levels of CDK1, CXCL13, IL1B, GADPH, TTK, ILF3, EWSR1, BIRC5, PLAUR, ISG20, and C1QBP were significantly lower (adjusted p < 0.05). Complete responders (CR) exhibited a distinct pattern of inflammatory gene expression pre-treatment relative to incomplete responders (IR), with alterations in 15 inflammatory pathways (p < 0.05) reflecting differential expression of 103 genes (p < 0.05). Presence of adverse effects was associated with improved treatment response. Differences in gene expression were found between pre-treatment samples in CR versus IR, suggesting that higher levels of inflammation pre-treament may play a part in regression of AKs. Further characterization of the immune micro-environment in AKs may help develop biomarkers predictive of response to topical immune modulators and may guide therapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Columbia University Irving Medical Center, Department of Dermatology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
2 Columbia University Irving Medical Center, Department of Medicine, Division of Hematology/Oncology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
3 Mount Sinai Hospital, Department of Dermatology, New York, USA (GRID:grid.416167.3)
4 University of Arizona Health Sciences, Department of Neurology, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
5 Columbia University Irving Medical Center, Department of Pathology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
6 Columbia University Irving Medical Center, Department of Surgery, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
7 Columbia University Irving Medical Center, Department of Pediatrics, Division of Hematology/Oncology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
8 Columbia University Irving Medical Center, Department of Medicine, Division of Hematology/Oncology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Herbert Irving Pavilion, New York, USA (GRID:grid.21729.3f)